doi: 10.1161/CIRCULATIONAHA.105.600676
(Circulation. 2006;113:336-337.)
© 2006 American Heart Association, Inc.
Editorial |
Coronary Artery Calcium
Should We Rely on This Surrogate Marker?
From the Robert Wood Johnson Foundation, Women’s Cardiovascular Services, UCSF Division of Cardiology, San Francisco, Calif.
Correspondence to Dr Rita F. Redberg, Robert Wood Johnson Foundation Health Policy Fellow, Professor of Medicine, Director, Women’s Cardiovascular Services, UCSF Division of Cardiology, 505 Parnassus Ave, Suite M-1180, School of Medicine, Division of Cardiology, San Francisco, CA 94143-0124. E-mail redberg@medicine.ucsf.edu
Key Words: Editorials • calcium • imaging • lipids
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
Surrogate markers of atherosclerosis such as treadmill time, serum tests, coronary artery calcium, and carotid intimal thickness enjoy considerable attention and the promise of yielding answers at much less cost and time than clinical trials using hard clinical outcomes such as myocardial infarction and cardiac death. Indeed, only studies with large sample sizes and long follow-up periods can provide meaningful data on hard outcomes. Of course, from a patient care perspective, the value of a surrogate marker derives solely from its ability to predict a cardiac event giving rise to either death or physical impairment that could be prevented. What is important to patients is whether a new therapy can make one feel better or live longer (or both). Few patients would eagerly undergo a new treatment if it would merely change a measurement but would not also improve how they felt, would not reduce their risk of heart attacks, and/or would not help them to live longer.
Article p 427
Cardiologists’ recent experience with hormone replacement therapy (HRT) once again illustrated the dangers of relying too heavily on surrogate markers. Multiple studies of HRT using surrogate markers showed a benefit on cardiovascular disease.1 The Postmenopausal Estrogen/Progestin Intervention (PEPI) trial, for example, showed that HRT had beneficial effect on serum markers of atherosclerosis, with lower low-density lipoprotein (LDL) and fibrinogen levels and higher high-density lipoprotein.2 The Rancho Bernado Study found that women taking HRT had lower coronary artery calcium (CAC) scores and concluded that there was antiatherogenic effect of postmenopausal
Related Article:
Circulation 2006 113: 427-437.
This article has been cited by other articles:
 |
|
 |
|
  R. S. Blumenthal, C.-W. Hwang, and K. Nasir Selective use of coronary artery calcium screening: worth the cost? J. Am. Coll. Cardiol., September 29, 2009; 54(14): 1268 - 1270. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rutten, I. Isgum, and M. Prokop Coronary Calcification: Effect of Small Variation of Scan Starting Position on Agatston, Volume, and Mass Scores Radiology, December 1, 2007; 246(1): 90 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Redberg Evidence, Appropriateness, And Technology Assessment In Cardiology: A Case Study Of Computed Tomography Health Aff., January 1, 2007; 26(1): 86 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Romanens and A. R. Miserez Letter by Romanens and Miserez Regarding Article, "Effect of Intensive Versus Standard Lipid-Lowering Treatment With Atorvastatin on the Progression of Calcified Coronary Atherosclerosis Over 12 Months: A Multicenter, Randomized, Double-Blind Trial" Circulation, September 19, 2006; 114(12): e506 - e506. [Full Text] [PDF]
|
|
|
|
|
|
A. Schmermund and R. Erbel Letter by Schmermund and Erbel Regarding Article, "Coronary Artery Calcium: Should We Rely on This Surrogate Marker?" Circulation, August 1, 2006; 114(5): e82 - e82. [Full Text] [PDF]
|
|